Impact of homologous recombination repair/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer.
Mike WenzelBenedikt HoehFlorestan KollClara HumkeAnne FasslHenning ReisPeter WildThomas SteuberMarkus GraefenDerya TilkiMiriam TraumannSeverine BanekFelix K H ChunPhilipp MandelPublished in: BJU international (2024)
Incidence of HRR alteration in a clinical real-world setting is high when using blood- and tissue-based tests. Patients with HRR/BRCA alterations have worse outcomes resulting in significant OS differences between HRR/BRCA-positive patients with mCRPC with and without PARPi usage vs HRR/BRCA-negative patients.
Keyphrases
- prostate cancer
- breast cancer risk
- end stage renal disease
- dna damage
- dna repair
- squamous cell carcinoma
- chronic kidney disease
- newly diagnosed
- ejection fraction
- small cell lung cancer
- risk factors
- prognostic factors
- radical prostatectomy
- copy number
- genome wide
- oxidative stress
- metabolic syndrome
- young adults
- weight loss
- dna methylation
- patient reported outcomes